EA201591345A1 - Способы лечения фиброза и рака - Google Patents

Способы лечения фиброза и рака

Info

Publication number
EA201591345A1
EA201591345A1 EA201591345A EA201591345A EA201591345A1 EA 201591345 A1 EA201591345 A1 EA 201591345A1 EA 201591345 A EA201591345 A EA 201591345A EA 201591345 A EA201591345 A EA 201591345A EA 201591345 A1 EA201591345 A1 EA 201591345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
treatment
fibrosis
methods
carboxymethylmethyloxyphenyl
Prior art date
Application number
EA201591345A
Other languages
English (en)
Other versions
EA031718B1 (ru
Inventor
Реми Анф
Дин Хам
Роберт Вальчак
Бенуа Ноэль
Original Assignee
Женфит
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женфит filed Critical Женфит
Publication of EA201591345A1 publication Critical patent/EA201591345A1/ru
Publication of EA031718B1 publication Critical patent/EA031718B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению соединения 1-[4-метилтиофенил]-3-[3,5-диметил-4-карбоксидиметилметилоксифенил]проп-2-ен-1-она в лечении фиброзных заболеваний и рака.
EA201591345A 2013-01-18 2014-01-20 Лечение фиброза и рака, связанных с тирозинкиназой EA031718B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305067 2013-01-18
PCT/EP2014/051060 WO2014111584A1 (en) 2013-01-18 2014-01-20 Methods of treatment of fibrosis and cancers

Publications (2)

Publication Number Publication Date
EA201591345A1 true EA201591345A1 (ru) 2015-11-30
EA031718B1 EA031718B1 (ru) 2019-02-28

Family

ID=47628079

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591345A EA031718B1 (ru) 2013-01-18 2014-01-20 Лечение фиброза и рака, связанных с тирозинкиназой

Country Status (26)

Country Link
US (2) US20150352065A1 (ru)
EP (1) EP2948137B1 (ru)
JP (1) JP6218854B2 (ru)
KR (1) KR102196277B1 (ru)
CN (1) CN105120855B (ru)
AU (1) AU2014206781B2 (ru)
CA (1) CA2897258C (ru)
CY (1) CY1121156T1 (ru)
DK (1) DK2948137T3 (ru)
EA (1) EA031718B1 (ru)
ES (1) ES2702038T3 (ru)
HK (1) HK1214773A1 (ru)
HU (1) HUE042569T2 (ru)
IL (1) IL239715B (ru)
LT (1) LT2948137T (ru)
MD (1) MD4629B1 (ru)
MX (1) MX361565B (ru)
NZ (1) NZ709420A (ru)
PH (1) PH12015501566B1 (ru)
PL (1) PL2948137T3 (ru)
PT (1) PT2948137T (ru)
SG (1) SG11201505281PA (ru)
SI (1) SI2948137T1 (ru)
TR (1) TR201819042T4 (ru)
WO (1) WO2014111584A1 (ru)
ZA (1) ZA201505151B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201819042T4 (tr) 2013-01-18 2019-01-21 Genfit Fibrozis ve kanserlerin tedavisine yönelik yöntemler.
EP3420082A4 (en) * 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
CN110536682B (zh) 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
TW202019870A (zh) 2018-08-03 2020-06-01 法商Ｇｅｎｆｉｔ公司 艾拉菲諾鹽
GB201901507D0 (en) * 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
KR20220140760A (ko) 2020-02-10 2022-10-18 장피트 엘라피브라노의 다형체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
KR101962209B1 (ko) 2009-11-26 2019-03-26 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
ES2384060B1 (es) * 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
TR201819042T4 (tr) 2013-01-18 2019-01-21 Genfit Fibrozis ve kanserlerin tedavisine yönelik yöntemler.

Also Published As

Publication number Publication date
PH12015501566A1 (en) 2015-09-21
AU2014206781A1 (en) 2015-07-16
KR102196277B1 (ko) 2020-12-29
SI2948137T1 (sl) 2019-01-31
ES2702038T3 (es) 2019-02-27
EA031718B1 (ru) 2019-02-28
US10792277B2 (en) 2020-10-06
DK2948137T3 (en) 2019-01-07
EP2948137B1 (en) 2018-11-14
CN105120855A (zh) 2015-12-02
JP2016506913A (ja) 2016-03-07
MD4629B1 (ru) 2019-05-31
PH12015501566B1 (en) 2015-09-21
PT2948137T (pt) 2018-12-20
IL239715A0 (en) 2015-08-31
HUE042569T2 (hu) 2019-07-29
WO2014111584A1 (en) 2014-07-24
NZ709420A (en) 2020-04-24
ZA201505151B (en) 2016-07-27
PL2948137T3 (pl) 2019-02-28
LT2948137T (lt) 2018-12-27
KR20150114497A (ko) 2015-10-12
MX2015009251A (es) 2015-10-15
JP6218854B2 (ja) 2017-10-25
HK1214773A1 (zh) 2016-08-05
CY1121156T1 (el) 2020-05-29
EP2948137A1 (en) 2015-12-02
MD20150076A2 (ru) 2015-11-30
IL239715B (en) 2019-06-30
CA2897258C (en) 2021-02-02
AU2014206781B2 (en) 2018-08-23
CN105120855B (zh) 2019-05-07
SG11201505281PA (en) 2015-08-28
TR201819042T4 (tr) 2019-01-21
US20170239213A1 (en) 2017-08-24
US20150352065A1 (en) 2015-12-10
CA2897258A1 (en) 2014-07-24
MX361565B (es) 2018-12-11

Similar Documents

Publication Publication Date Title
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
EA201790413A1 (ru) Антитела против tigit
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691940A1 (ru) Новые соединения
EA201590987A1 (ru) Соединения и способы их применения
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201590997A1 (ru) Соединения и способы их применения
WO2015009726A3 (en) Medical uses of cd38 agonists
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
CY1121156T1 (el) Μεθοδοι αντιμετωπισης ινωσης και καρκινων
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EA201501177A1 (ru) Фармацевтические композиции
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM